Gulf Pharmaceutical Industries P.S.C.

ADX:JULPHAR Stock Report

Market Cap: د.إ1.7b

Gulf Pharmaceutical Industries P.S.C Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Basel Nimer Ziyadeh

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.2yrs
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Mar 25
Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26
Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08
Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14
Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

CEO

Basel Nimer Ziyadeh

2.2yrs

Tenure

Mr. Basel Nimer Ali Ziyadeh is Chief Executive Officer of Gulf Pharmaceutical Industries P.S.C. from February 2023. Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming th...

Leadership Team

NamePositionTenureCompensationOwnership
Basel Nimer Ziyadeh
Chief Executive Officer2.2yrsno datano data
Khalid Malkawi
Chief Financial Officer1.3yrsno datano data
Malik Metahri
Chief Technical Officer2.3yrsno datano data
Adel Khalaf
General Counsel & Chief Compliance Officer5.3yrsno datano data
Hosam Badr
Marketing Director11.1yrsno datano data
Juergen Lauterbach
Chief Corporate Development & Strategy Officer2.7yrsno datano data
Gopa Kumar
Chief Human Resources Officer5.3yrsno datano data
Alaa Gamal
Chief Commercial Officer1.3yrsno datano data
Rayan Omer
Company Secretaryno datano datano data

2.5yrs

Average Tenure

Experienced Management: JULPHAR's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Abdulaziz Al Zaabi
Director8.3yrsno datano data
Rabih Khouri
Vice-Chairman of the Board3.7yrsno datano data
Raman Garg
Independent Director5.1yrsno datano data
Jean Diab
Director2yrsno datano data
Saqer Bin Al Qassimi
Chairman of the Board20.3yrsno datano data
Medhat Mohamed Al Gamal
Director6.3yrsno datano data
Abboud Bejjani
Director5.3yrsno datano data
Olfa Gam
Director3.7yrsno datano data
Hamodi Abas Al limy
Director2.8yrsno datano data

5.1yrs

Average Tenure

Experienced Board: JULPHAR's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/27 16:33
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gulf Pharmaceutical Industries P.S.C. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rim Ben Salah GharbiAlphaMena
null RESEARCH DEPARTMENTPrime Research